Published: 15 November 2011
Since 1996, 15 US states and the District of Columbia have passed laws permitting personal possession of a defined amount of cannabis for medical use. The patient must have a written recommendation from a doctor in all states except California and Maine, where the recommendation can be oral. All states except Washington have established confidential registries with patient identity cards, and in a number of states these are mandatory. While each state has its own list of conditions, most states allow cannabis use to treat pain, whether ‘chronic’, ‘severe’ or ‘intractable’.
Almost all states have adopted the caregiver model, whereby a designated person is permitted to grow a limited quantity of cannabis for the use of the patient. Depending on the state, patients may designate one or two caregivers, and caregivers may supply up to five patients. The amounts permitted range from 1 ounce — about 28 grams — (Alaska, Montana, Nevada) to 24 ounces (Oregon, Washington) of usable herbal cannabis, and from six to 24 plants, some of which should be ‘immature’. Provision of cannabis for medical use by not-for-profit dispensaries or state treatment centres is permitted in about half of the states. In all but two jurisdictions, New Jersey and Washington DC, patients are allowed to grow their own medicinal cannabis.
Federal law, in contrast, classifies cannabis as a dangerous substance with no medical use. This allows the federal government to prosecute any users and suppliers of cannabis. However, in October 2009, the Deputy Attorney General issued a memo to federal prosecutors not to prioritise the prosecution of cases relating to medical use of cannabis if authorised under state law.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
Cais do Sodré
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11
Monitoring and analysing the nature and scale of the drugs phenomenon in Europe is a central part of the EMCDDA's work. The Statistical bulletin is published yearly by the EMCDDA and provides access to the most recent data on the drug situation in Europe. Access data »
The countries section makes it easier than ever to find drug-related information and data by country. Each page brings together all of our available products by topic or format for the country in question. Countries »
Drug profiles are scientifically sound descriptions of drugs.
Our publications are tailored to the needs of specific audiences and published in a variety of print or web formats. Access the Publications database.
Annual report | Drugnet Europe | Drug policy profiles | Drugs in focus | Implementation reports | Insights | Joint publications | Joint reports | Literature reviews | Manuals | Monographs | National reports | Risk assessments | Selected issues | Technical data sheets | Thematic papers
The annual report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field. It is available for download in PDF in 22 languages.
To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations unit:
Head of sector
Media relations and marketing
Tel: (351) 211 21 02 00/32
Fax: (351) 21 813 1711
Maria José Louro
Media relations assistant
Tel: (351) 211 21 02 00/40
Fax: (351) 21 813 1711
Page last updated: Friday, 28 October 2011